{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:02:04Z","timestamp":1785193324788,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Heparin-induced thrombocytopenia type II (HIT II) is a rare, immune-mediated complication of heparin therapy and can cause life-threatening thromboembolism. However, perioperative anticoagulation therapy for patients with a complication of HIT II has not been established.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 6-year-old boy with tetralogy of Fallot underwent radical intracardiac repair with administration of argatroban at 1\u2009year old due to positive HIT antibody. Reoperation was scheduled for pulmonary valve insufficiency, using argatroban and nafamostat mesilate as anticoagulants. Argatroban has a long onset time and the activated coagulation time (ACT) requires 7\u201326\u2009h to return to the preadministration level, making hemorrhage control difficult, while half-life of nafamostat mesilate is shorter than that of argatroban. Celite ACT reflects the effects of both argatroban and nafamostat mesilate, but kaolin ACT reflects only the effect of argatroban. Due to the early termination of argatroban administration based on Celite and kaolin ACTs, ACT recovered to \u2264\u2009200\u2009s at 5\u2009h after the end of argatroban administration.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Celite and kaolin ACTs can be used as markers to obtain close control of the required dose of argatroban in combination with nafamostat mesilate for the management of HIT II patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40981-020-0310-6","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T18:03:17Z","timestamp":1578938597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report"],"prefix":"10.1186","volume":"6","author":[{"given":"Shuji","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Kusudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"310_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1378\/chest.11-2303","volume":"141","author":"LA Linkins","year":"2012","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:495\u2013530. https:\/\/doi.org\/10.1378\/chest.11-2303 PMID: 22315270.","journal-title":"Chest."},{"key":"310_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","volume":"661","author":"S Fujii","year":"1981","unstructured":"Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661:342\u20135. https:\/\/doi.org\/10.1016\/0005-2744(81)90023-1 PMID: 6271224.","journal-title":"Biochim Biophys Acta"},{"key":"310_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000215139","volume":"15","author":"Y Hitomi","year":"1985","unstructured":"Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15:164\u20138. https:\/\/doi.org\/10.1159\/000215139 PMID: 3161808.","journal-title":"Haemostasis"},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4009\/jsdt1985.21.621","volume":"21","author":"H Kojima","year":"1988","unstructured":"Kojima H, Akizawa T, Kitaoka T, Koshikawa S, Kazama M, Koshiyama Y, et al. Evaluation of short-acting anticoagulants for hemodialysis\u2014optimum method of estimating anticoagulation. J Jpn Soc Dial Ther. 1988;21:621\u20137. https:\/\/doi.org\/10.4009\/jsdt1985.21.621.","journal-title":"J Jpn Soc Dial Ther"},{"key":"310_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"34","author":"TE Wertentin","year":"2001","unstructured":"Wertentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;34:1286\u201392. https:\/\/doi.org\/10.1056\/NEJM200104263441704 PMID: 11320387.","journal-title":"N Engl J Med"},{"key":"310_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00000539-200302000-00009","volume":"96","author":"GA Nuttall","year":"2003","unstructured":"Nuttall GA, Oliver CO, Santrach PJ, McBane RD, Erpelding DB, Marver CL, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg. 2003;96:344\u201350. https:\/\/doi.org\/10.1097\/00000539-200302000-00009 PMID: 12538175.","journal-title":"Anesth Analg"},{"key":"310_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJM200008173430718","volume":"343","author":"B Potzsch","year":"2000","unstructured":"Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patient with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515. https:\/\/doi.org\/10.1056\/NEJM200008173430718 PMID: 10950681.","journal-title":"N Engl J Med"},{"key":"310_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2491\/jjsth.19.195","volume":"19","author":"S Miyata","year":"2008","unstructured":"Miyata S, Yamamoto H. The treatment of heparin-induced thrombocytopenia (HIT). Jpn J Thromb Hemost. 2008;19:195\u20138. https:\/\/doi.org\/10.2491\/jjsth.19.195.","journal-title":"Jpn J Thromb Hemost"},{"key":"310_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1067\/mtc.2001.116940","volume":"12","author":"K Furukawa","year":"2001","unstructured":"Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg. 2001;12:1255\u20136. https:\/\/doi.org\/10.1067\/mtc.2001.116940 PMID: 11726911.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"310_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMra044440","volume":"353","author":"DN Marcello","year":"2005","unstructured":"Marcello DN, Saskia M, Harry RB. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028\u201340. https:\/\/doi.org\/10.1056\/NEJMra044440 PMID: 16148288.","journal-title":"N Engl J Med"},{"key":"310_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1053\/j.jvca.2009.12.001","volume":"24","author":"K Azuma","year":"2010","unstructured":"Azuma K, Maruyama K, Imanishi H, Nakagawa H, Kitamura A, Hayashida M. Difficult management of anticoagulation with argatroban in a patient undergoing on-pump cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24:831\u20133. https:\/\/doi.org\/10.1053\/j.jvca.2009.12.001 PMID: 20138550.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"310_CR12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/s0003-4975(02)04782-3","volume":"75","author":"JT Edwards","year":"2003","unstructured":"Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg. 2003;75:1622\u20134. https:\/\/doi.org\/10.1016\/s0003-4975(02)04782-3 PMID: 12735590.","journal-title":"Ann Thorac Surg"},{"key":"310_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/1089253215624766","volume":"20","author":"GJ Latham","year":"2016","unstructured":"Latham GJ, Jefferis Kirk C, Falconer A, Dickey R, Albers EL, McMullan DM. Challenging argatroban management of a child on extracorporeal support and subsequent heart transplant. Semin Cardiothorac Vasc Anesth. 2016;20:168\u201374. https:\/\/doi.org\/10.1177\/1089253215624766 PMID: 26721808.","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"310_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1600-0609.2006.00786.x","volume":"78","author":"ME Martin","year":"2007","unstructured":"Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol. 2007;78:161\u20136. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00786.x PMID: 17328717.","journal-title":"Eur J Haematol"},{"key":"310_CR15","first-page":"2166","volume":"41","author":"H Takano","year":"1993","unstructured":"Takano H, Miyamoto Y, Kaneko M, Matsuwaka R, Kuratani T, Amemiya A, et al. Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit. J Jpn Assn Thorac Surg. 1993;41:2166\u201373.","journal-title":"J Jpn Assn Thorac Surg"},{"key":"310_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4326\/jjcvs.40.112","volume":"40","author":"H Kato","year":"2011","unstructured":"Kato H, Yashiki N, Iino K, Tomita S, Watanabe G. A case of re-operation for paravalvular leakage after mitral valve replacement complicated by heparin-induced thrombocytopenia. Jpn J Cardiovasc Surg. 2011;40:112\u20134.","journal-title":"Jpn J Cardiovasc Surg"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-0310-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40981-020-0310-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-0310-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T01:18:11Z","timestamp":1610414291000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-020-0310-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1186\/s40981-020-0310-6","relation":{},"ISSN":["2363-9024"],"issn-type":[{"value":"2363-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from the parent of the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}